Acurx Pharmaceuticals develops antibiotics, including ibezapolstat, to fight bacterial infections in patients, particularly clostridium difficile. ACX-375C is another antibiotic treatment being developed to target gram-positive bacteria such as methicillin-resistant staphylococcus aureus. The company was incorporated in 2017 and is based in Staten Island, New York.